 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
Acute Myelogenous Leukemia (AML) OutcomesThe survival graphs below illustrate outcomes of unrelated donor hematopoietic cell transplants (bone marrow, PBSC, or cord blood transplants — BMT) coordinated by the National Marrow Donor Program (NMDP) for both adult and pediatric patients.
On this page:NMDP outcomes for adult AML patientsFive-year survival for adult patients (> 18 years of age) transplanted for acute myelogenous leukemia (AML) using marrow (Figure 1) or peripheral blood stem cells (PBSC) (Figure 2) is significantly increased in patients transplanted in first or second complete remission compared to those patients transplanted with advanced disease (log-rank p-value < 0.0001). Unrelated transplant for AML in first complete remission is indicated if the patient has poor-risk cytogenetics at diagnosis or induction failure.In a 2007 study of 261 AML patients undergoing matched unrelated donor transplantation, cytogenetic risk factors had no effect on five-year overall survival and DFS for patients in first complete remission. In second complete remission, there was a non-significant trend toward better survival for patients with favorable cytogenetics. The researchers concluded that matched unrelated donor transplantation should be considered for patients with unfavorable cytogenetics lacking a suitable HLA-matched sibling donor. [1] A large-scale, multi-center phase III clinical trial is underway to determine if graft source (PBSC or marrow) affects transplant outcomes in unrelated donor transplantation for AML and other hematologic malignancies. The trial is being conducted through the Blood and Marrow Transplant Clinical Trials Network (BMT CTN Study 0201). [2]
Acute myelogenous leukemia: Survival of adult PBSC myeloablative transplant patients by disease stage 1998-2006. (NMDP data)  View larger version Download slide (PPT)
 NMDP outcomes for pediatric AML patientsFive-year survival for pediatric patients (<18 years of age) transplanted for AML is significantly increased for those patients transplanted in second complete remission compared to those transplanted in first complete remission or with advanced disease. However, a greater percent of patients transplanted in first complete remission had poor-risk cytogenetics compared to those patients who were transplanted in second complete remission (log-rank p-value < 0.0004). Unrelated transplant for AML in first complete remission is indicated if the patient has poor-risk cytogenetics at diagnosis or induction failure.
NMDP outcomes for adult AML patients > age 55Due to their lowered toxicity, non-myeloablative or reduced-intensity transplants have expanded the number of patients eligible for hematopoietic cell transplantation. For more information, see Advances in Conditioning Regimens. Figure 4 shows five-year survival for adult patients 55 years of age or older undergoing non-myeloablative transplantation for AML.
References
|
|
 E-mail a Friend Print this Page    |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
